Remote vs. In-Person Study Evaluation (RISE) Trials: RISE Above Opioid Overdose (Trial 3 of 3)

Part of paid clinical trials in Oklahoma City, Oklahoma.

Sponsor
State University of New York at Buffalo
Study ID
NCT07875569
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • In-person Visits
  • Remote Visits
  • Remote vs. In-Person

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Accepted

Interventions

  • Opioid Overdose Prevention Training — BEHAVIORAL
    All participants receive a brief training video for the use of naloxone for opioid overdose prevention and a naloxone kit.

Study Details

The study will employ a randomized, parallel-group design with two-stage randomization. After an initial brief screen for basic eligibility, participants will be randomized (within site) to either Remote (R) or In-Person (IP) Intake Groups. During the Intake, detailed consent and eligibility assessment will be completed. Participants who are eligible at the Intake will be randomized (within site and Intake Group) to R or IP Treatment and Assessment Groups. Participants will be followed for 3 months.

Key Dates

First listed
Oct 15, 2026
Start date
Nov 30, 2026
Status verified
Oct 2026
Primary completion
May 31, 2028
Completion
May 31, 2028

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Other: REMOTE intake AND REMOTE treatment/assessment
    In this arm, ppts have been randomly assigned to a REMOTE INTAKE eligibility/baseline visit, and subsequently randomized to 5 REMOTE treatment/assessment visits.
  • Other: REMOTE intake BUT IN-PERSON treatment/assessment
    In this arm, ppts have been randomly assigned to a REMOTE INTAKE eligibility/baseline visit, and subsequently randomized to 5 IN-PERSON treatment/assessment visits.
  • Other: IN-PERSON intake, BUT REMOTE treatment/assessment
    In this arm, ppts have been randomly assigned to an IN-PERSON INTAKE eligibility/baseline visit, and subsequently randomized to 5 REMOTE treatment/assessment visits.
  • Other: IN-PERSON intake AND IN-PERSON treatment/assessment
    In this arm, ppts have been randomly assigned to an IN-PERSON INTAKE eligibility/baseline visit, and subsequently randomized to 5 IN-PERSON treatment/assessment visits.

Primary Outcome Measure

Accrual efficiency/Pre-treatment visits [ Time Frame: ~1 month ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Oklahoma Health CampusOklahoma CityOklahoma73104
Karen Cropsey, PsyD
[email protected]
405-271-5121

Find similar trials in Oklahoma City, OK

By research site
University of Oklahoma Health Campus· Oklahoma City, OK

Related Studies